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Abstract 62 
 63 
Objective: Epidemiological data suggest low serum 25-hydroxyvitamin D3 (25-OH-D3) levels are 64 
associated with radiological progression of knee osteoarthritis (OA). This study aimed to assess 65 
whether vitamin D supplementation can slow the rate of progression. 66 
Method:  A 3 year, double-blind, randomised, placebo-controlled trial of 474 patients aged over 50 67 
with radiographically evident knee OA comparing 800 IU cholecalciferol daily with placebo. Primary 68 
outcome was difference in rate of medial joint space narrowing (JSN). Secondary outcomes 69 
included lateral JSN, Kellgren and Lawrence grade, WOMAC pain, function, stiffness and the Get up 70 
and Go test. 71 
Results: Vitamin D supplementation increased 25-OH-D3  from an average of 20·7 (SD 8·9) μg/L to 72 
30·4 (SD  7·7) μg/L, compared to 20·7 (SD  8·1) μg/L and 20·3 (SD  8·1) μg/L in the placebo group. 73 
There was no significant difference in the rate of JSN over three years in the medial compartment of 74 
the index knee between the treatment group (average -0.01 mm/year) and placebo group (-0.08 75 
mm/year), average difference 0.08 mm/year, (95% CI [ -0·14 to 0·29], p=0.49).  No significant 76 
interaction was found between baseline vitamin D levels and treatment effect.  There were no 77 
significant differences for any of the secondary outcome measures. 78 
Conclusion: Vitamin D supplementation did not slow the rate of JSN or lead to reduced pain, 79 
stiffness or functional loss over a three year period. On the basis of these findings we consider that 80 
vitamin D supplementation has no role in the management of knee OA. 81 
 82 
Abstract word count: 240/250 83 
 84 
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Introduction 86 
 87 
Knee Osteoarthritis (OA) is a chronic, painful disease associated with considerable morbidity, costs 88 
and disability 1. In the U.S., it is estimated that over a third of people aged over 60 have radiographic 89 
knee OA2 and over 50% of these with knee OA will go on to have a total knee replacement in their 90 
lifetime3.  At present there are no licensed treatments that alter disease progression and 91 
management is primarily concerned with symptom control to retain or improve joint function. 92 
 93 
Vitamin D deficiency (defined as 25-hydroxyvitamin D3(25-OH-D3) serum levels below 20μg/mL 
4 5) is 94 
common in the UK with estimates of over 12% for people living in private households and 30% of 95 
care home residents in the over 65s. There has been considerable interest in the association 96 
between vitamin D deficiency and OA incidence and progression. Vitamin D has a number of 97 
important biological functions in bone, cartilage and muscle6 which has led to the hypothesis that 98 
vitamin D supplementation may prevent the progression of OA. There is evidence from a number of, 99 
but not all, epidemiological studies suggesting that low dietary intake of vitamin D and low serum 25-100 
OH-D3 levels are associated with increased radiological progression of knee OA 
7-13. Epidemiological 101 
data from the Framingham Study demonstrated that low vitamin D intake was associated with a 102 
three to four-fold increased risk of radiographic progression at two skeletal sites over 8-10 years.7 103 
Further analysis of a separate cohort of patients in the Framingham study, along with another cohort 104 
from the Boston Osteoarthritis of the Knee Study (BOKS) found no association between vitamin D 105 
status and joint space or cartilage loss in knee OA 12. 106 
 107 
Findings from RCTs have thus far not conclusively settled this debate 14-17. A 12 month trial of vitamin 108 
D in 107 vitamin D insufficient subjects with knee OA found a small but statistically significant 109 
improvement in pain 14.  A trial of 146 subjects with symptomatic knee OA found that vitamin D 110 
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supplementation for two years had no effect on the structural progression of OA using MRI as the 111 
primary outcome 16. A further post hoc analysis of a RCT concluded that calcium plus vitamin D 112 
supplementation for two years in post-menopausal women had no effect on self-reported frequency 113 
or severity of joint symptoms 17. As these trials were heterogeneous in terms of patients recruited, 114 
sample sizes and some also used calcium in addition to vitamin D supplements, it is important to 115 
have a large RCT with a prolonged follow up to provide further clarity on the role of vitamin 116 
supplementation in patients with knee OA. 117 
 118 
Aim 119 
 120 
The primary aim of this trial was to determine whether vitamin D supplementation can reduce the 121 
rate of structural progression of knee OA as measured by change in medial joint space assessed on a 122 
weight-bearing radiograph over a 3-year period. Secondary outcomes included changes in pain and 123 
function. 124 
 125 
Methods 126 
 127 
Study design 128 
 129 
The VIDEO study was a double-blind, randomised, placebo-controlled trial performed at five UK NHS 130 
hospitals. Participants were randomly assigned to receive either 800IU of oral cholecalciferol or 131 
matched placebo daily. Data from clinical trials indicated that 800IU/day of cholecalciferol can 132 
produce significant increases in serum 25-hydroxyvitamin D3 levels and that these increases are 133 
evident within one month of starting treatment18.  The protocol was approved by the Scotland A 134 
Research Ethics Committee and the trial was registered with EudraCT: ref. 2004-000169-37, 135 
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ISRCTN94818153, CTA No. 11287/0001/001. The trial was conducted in accordance with Good 136 
Clinical Practice guidelines and the Declaration of Helsinki. 137 
 138 
Participants were identified from GP lists, patient referrals to hospitals and via radio advertisements. 139 
Patients were eligible if they: were aged >50 years, ambulatory, had radiological evidence of knee 140 
OA at medial tibio-femoral knee compartment (Modified Kellgren & Lawrence (K&L) score 2/3, JSW 141 
>1mm) and knee pain for most days of the previous month. Reasons for exclusion were: secondary 142 
OA, inflammatory arthritis, early morning knee stiffness for >30 minutes, cod liver oil or vitamin 143 
supplementation containing vitamin D >200 IU, glucosamine or chondroitin use for <three months, 144 
osteoporotic fracture, previous knee surgery or arthroscopy within six months, use of 145 
bisphosphonates within two years. Eligible participants were invited to a screening appointment. 146 
Informed consent was taken along with knee radiographs, which were assessed by the local clinician 147 
to determine eligibility. 148 
 149 
Randomisation and blinding 150 
 151 
Eligible participants were randomised centrally by the UK Medical Research Council Clinical Trials 152 
Unit (MRC CTU) via telephone to receive either oral vitamin D or matching placebo tablets (1:1) by 153 
computer-generated randomisation with stratification by recruitment centre. Treatment allocation 154 
was concealed from the patients, clinicians, outcome assessors and investigators. Both the active 155 
treatment and placebo were manufactured by Thompson and Capper Ltd, and packed by Bilcare 156 
Global Clinical Supplies (Europe) Ltd. 157 
 158 
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Trial procedures 159 
 160 
At the baseline visit knee bilateral radiographs and blood samples were taken, and the assigned drug 161 
dispensed in six month packs. Radiographs and blood sampling were repeated at 12 months and 36 162 
months. Questionnaires (WOMAC) were completed at 6-monthly intervals until the final visit. Blood 163 
was drawn to measure serum 25-OH-D3 at baseline and 12 months to assess baseline vitamin D 164 
status and response to supplementation. Serum vitamin D2 and D3 concentrations were assayed at 165 
King’s College Hospitals NHS Foundation Trust via mass spectrophotometry using the MassChrom 166 
reagent kit (Chromsystems Instruments & Chemicals GmbH).  167 
 168 
Outcome measures 169 
 170 
The primary outcome measure was radiological progression of knee OA in the medial joint 171 
compartment of the index knee (knee with the smallest joint space width (JSW) at baseline in the 172 
case of bilateral disease), as measured by the rate of JSN (mm/year) over the three years. Knee X-173 
rays were taken using the MTP technique 19 using a foot map to improve accurate re-positioning at 174 
follow up visits.  175 
All joint space measurements were performed by a single reader. Reproducibility was excellent, and 176 
comparable to previous results using the same software package 20, 21; intra-rater intra-class 177 
correlation coefficients (ICCs) were: 0·96 medial 95% CI [0·88-0·98], 0·98 lateral 95% CI [0·94 0·99].  178 
Secondary outcomes measures included: rates of change in minimum JSW of the lateral 179 
compartment, and of the medial and lateral compartments of the contralateral knee, Kellgren and 180 
Lawrence (K&L)22, 23 grade, WOMAC VAS scores (0-100 pain, stiffness, function and total) in the index 181 
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knee, and Get up and Go test. Baseline and follow-up X-rays were graded for K&L grade by a Clinical 182 
Orthopaedic Fellow, with an intra-reader Kappa of 0·68.  183 
 184 
Sample size 185 
 186 
The study was designed to detect a clinically important mean difference of 0·22mm/year in the rate 187 
of JSN between treatment groups over three years, assuming a standard deviation of 0·7 mm 24, 25, 188 
with 80% power at the 5% significance level. Allowing for 32% drop-out rate, the total sample size 189 
required was 470. 190 
 191 
Statistics 192 
 193 
Analysis was conducted following the intention-to-treat principle and in accordance with a pre-194 
specified analysis plan which was finalised prior to database lock and breaking the blind.  195 
To assess JSN a longitudinal analysis was performed using a linear mixed regression model with fixed 196 
effects for treatment, time, treatment by time and adjustment for: baseline JSW, centre, gender, 197 
glucosamine or chondroitin use, age and BMI. To allow for between patient differences the model 198 
included a random patient intercept. The central parameter of interest was the treatment by time 199 
interaction, which represents the average difference in the rate of JSN/year between the treatment 200 
groups. Continuous secondary outcomes were analysed similarly. Changes in ordinal outcomes over 201 
time were analysed using ordinal logistic regression models with robust Huber-White sandwich 202 
estimators of standard errors. The effect of treatment on the proportion of patients with clinically 203 
significant progression (JSN>0·5mm in the index knee) at three years was obtained using a Poisson 204 
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regression model with robust error estimates. For patients who had a total knee replacement (TKR) 205 
in the index knee during the trial, clinically significant progression was assumed. 206 
Mean imputation was used to deal with missing covariate values 26. For patients who had TKR during 207 
the trial, data before surgery was included and data after surgery assumed to be missing.  All missing 208 
outcome values were assumed to be missing at random and multiple imputation by chained 209 
equations was used 27, 28. Sensitivity analyses, including analysis of the complete cases and a range of 210 
missing not at random mechanisms, were performed to assess the robustness of the primary results 211 
to the effect of missing data (for full details see supplementary file eTable 2 and eFigure 1). All 212 
statistical analyses were performed using Stata/IC version 12·1 (StataCorp, College Station, TC, USA). 213 
 214 
Results 215 
 216 
In total, 474 participants were recruited between 19/01/2005 and 13/06/2008. Table 1 shows 217 
baseline clinical data and baseline radiographic characteristics. Additional baseline variables can be 218 
found in the supplementary file, eTable 1. The treatment and placebo groups were well matched for 219 
clinical characteristics and showed a similar distribution of radiographic characteristics. The 220 
distribution of serum 25-OH-D3, divided into tertiles (table 3), was almost identical in the two 221 
groups, with 50% of both groups vitamin D3 deficient (<20μg/L).  222 
As shown in Figure 1, 198 of participants in the placebo group (84%) and 188 of those in the 223 
treatment group (79%) attended the 3-year follow-up visit. Six patients in the placebo group and 224 
seven in the vitamin D group received a TKR of the index knee during the follow up period. Due to a 225 
combination of technical and logistic reasons, including poor positioning and quality a number of 226 
radiographs from attending patients, including baseline, could not be evaluated for JSW accurately.  227 
JSW in the medial compartment of the index knee was missing for a total of 37/474 patients (8%) at 228 
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baseline (18/237 placebo, versus 19/237 active), 110/474 patients (23%) at year one (58/237 229 
placebo versus 52/237 active) and 183/474 (39%) at year three (87/237 placebo versus, 96/237 230 
active). 38% of the missingness at year one (42/110) was due to unreadable X-rays (23 placebo and 231 
19 active). 30% of the missingness at year three (55/183) was due to unreadable X-rays (27 placebo 232 
versus 28 vitamin D).  The remaining missingness at year three occurred due to withdrawal 54% 233 
(99/183, 49 placebo (3 with TKR of index knee at one year) and 50 active (1 with TKR of index knee at 234 
one year)), loss to follow-up 10% (18/183, 7 placebo and 11 active), TKR of the index knee at year 235 
three 5% (9/183, 3 placebo and 6 active) or death 1% (2/183, 1 placebo and 1 active).  Missingness 236 
of X-ray data did not vary by treatment arm. 380/474 patients (189/237 placebo, 191/237 active) 237 
had baseline and at least one follow up JSW reading available and were analysed separately as a 238 
sensitivity analysis. A separate analysis of the 242/474 patients (125/237 placebo, 117/237 active) 239 
with complete follow-up was also performed along with additional sensitivity analysis to assess the 240 
impact of missing data (supplementary file eTable 2 and eFigure 1). 241 
 242 
Vitamin D analysis 243 
 244 
At 12 months, serum vitamin D3 levels had increased from an average of 20·7 (8·9) μg/L at baseline 245 
to 30·4 (7·7) μg/L in the vitamin D group. Levels decreased for those receiving placebo from 20·7 246 
(8·1) μg/L at baseline to 20·3 (8·1) μg/L at 12 months (table 3). The number of patients with vitamin 247 
D deficiency (<20 g/L) fell to 7% in the vitamin D group but rose to 54% in the placebo group.  248 
 249 
Radiographic results  250 
 251 
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There was no significant difference in the rate of JSN over three years in the medial compartment of 252 
the index knee between treatment groups (-0.01mm/year versus -0.08mm/year for vitamin D and 253 
placebo respectively), between group difference 0·08 mm/year, 95% CI [-0·14 to 0·29], p=0·49 254 
(figure 2, table 2). Sensitivity analyses conducted to assess the effect of missing values on the 255 
estimated treatment effect produced results no different from the primary analysis (supplementary 256 
file eTable 2 and eFigure 1).  No interaction between baseline vitamin D status and treatment effect 257 
() was found (<20 µg/L,  0·06, 95% CI [-0·20 to 0·32]; 20 µg/L to 30 µg/L,  0·05, 95% CI [-0·20 to 258 
0·29]; >30 µg/L,  0·05, 95% CI [-0·30 to 0·40]) (Figure 3). 259 
There was no difference in the proportion of patients with clinically significant progression of JSN 260 
(JSN>0.5mm in the index knee) at three years between the vitamin D group (39%) and placebo group 261 
(37%). The absolute risk difference was 2% (95% CI [-10% to 14%], p = 0.76) (Table 2).  262 
We explored the hypothesis that there may be an interaction between treatment effect and baseline 263 
JSN. The interaction did not reach significance (p=0·86, N = 474).  264 
 265 
Secondary outcomes 266 
 267 
The placebo group showed an increase in WOMAC pain whereas the vitamin D group showed a small 268 
decrease (0.71 versus -0.08 per year, between group difference -0.79, 95% CI [-2.31 to 0.74], table 2, 269 
eFigure 2). WOMAC stiffness decreased in both groups (-2·02 versus -0.50 per year for vitamin D and 270 
placebo groups respectively, between group difference -1.52, 95% CI [-3.24 to 0.21]). WOMAC 271 
function increased for both groups (0.42 versus 1.07 per year for vitamin D and placebo, between 272 
group difference -0·65, 95% CI [-2·09 to 0·79]) . None of the above differences achieved statistical 273 
significance.  274 
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Odds ratios of a higher K&L grade per year were calculated as 1.32 (Vitamin D) and 1.23 (placebo) for 275 
the index knee and 1.19 (Vitamin D) and 1.18 (placebo) for the contralateral knee. This gave a 276 
treatment by time odds ratio, which represents the increase in odds of a higher K&L grade per year 277 
for vitamin D patients relative to placebo, of 1.07 (95% CI [0.88 to 1.31]) for the index knee and 1.01 278 
(95% CI [0.80 to 1.27]) for the contralateral knee (Table 2).  The odds of a higher get up and go test 279 
grade per year for Vitamin D patients was 1.00 and 1.04 for placebo patients. There was no 280 
significant difference in the odds of a higher get up and go test grade over time between the 281 
treatment groups (OR = 0.96, 95% CI [0.73 to 1.27]). Additional secondary outcomes were assessed 282 
and treatment effect estimates can be found in the supplementary file eTable 4. All outcomes at 283 
three years are summarised in eTable 5.  284 
 285 
Adverse events 286 
 287 
There was no difference in the proportion of patients experiencing SAE’s between the vitamin D 288 
(59/237, 25%) and placebo group (64/237, 27%), p = 0.67. Only 2 SAE’s were classified as possibly 289 
related to treatment (one placebo with pancreatitis and one vitamin D with calculus ureteric), the 290 
remaining SAE’s were classified as unrelated to treatment.  There were no differences  in the rates of 291 
occurrence of hypercalcaemia (five placebo, three vitamin D) or hypercalciuria (34 placebo, 46 292 
vitamin D). 293 
 294 
Discussion 295 
 296 
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There is no clear evidence that vitamin D supplementation, at a dose of 800 IU cholecalciferol daily, 297 
had an effect on the progression of knee OA over the three year period, as measured by changes in 298 
JSW, or on knee pain, function or stiffness. This is despite the fact that participants had high rates of 299 
vitamin D deficiency at trial entry, and the level of supplementation was sufficient to increase serum 300 
vitamin D levels by 10 μg/L on average in the first year of treatment, reducing the proportion of 301 
participants with deficiency by over 80%.  302 
Previous research has not provided a consensus on the effect of vitamin D on the progression of 303 
knee OA, with observational studies and RCTs generating conflicting findings. Several high quality 304 
epidemiologic studies have demonstrated an association between low serum vitamin D and /or 305 
vitamin D intake and the risk of either OA incidence or progression 8-11, however others have shown 306 
no association 12, 13, 15, 29-31. These studies vary in methodology and were also subject to a number of 307 
important biases.   308 
McAlindon performed a two year RCT of 2000 IU/day oral cholecalciferol for patients with 309 
symptomatic knee OA. The primary outcomes were knee cartilage volume loss measured by MRI and 310 
knee pain by WOMAC.  The population studied had similar baseline concentrations of vitamin D but 311 
greater baseline JSW (approximately 5mm vs. 3.5mm).  The results demonstrated that despite 61.3% 312 
of patients achieving target concentrations of vitamin D, there were no significant improvements 313 
over placebo in any of the outcomes. Sanghi et al performed a 12 month RCT of vitamin D 314 
supplementation in patients with knee OA and vitamin D deficiency 15. They demonstrated a 315 
statistically significant reduction in pain and increase in physical function in a group taking vitamin D 316 
compared with placebo, however the difference between the two groups was not deemed to be 317 
clinically important 32. Jin et al performed a two year RCT of vitamin D supplementation, also in 318 
patients with knee OA and low vitamin D levels. The primary outcomes were knee cartilage volume 319 
loss measured by MRI and knee pain by WOMAC. No reduction in knee cartilage volume loss of pain 320 
was observed33. 321 
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The results from our study, which in comparison to the previous studies is the largest pragmatic trial 322 
with inclusion of non-vitamin D deficient patients, are consistent with the above results. The VIDEO 323 
trial contributes several new findings. Firstly, we measured JSN and K&L grade in the contra-lateral 324 
knee.  This is important as pathogenic mechanisms may be different in the contra-lateral joint 325 
compared with the index knee which exhibits later stage disease in patients with bilateral OA, as 326 
suggested in the Doxycycline trial by Brandt et al 25. In addition, we measured JSN in the medial and 327 
lateral compartments individually. Although medial compartment disease is far more prevalent, and 328 
the majority of previous studies focus only on joint space changes in the medial compartment 4, 25, it 329 
is important to measure JSN in the lateral compartment to ensure disease progression is not missed 330 
34. We looked at the association of the treatment effect with baseline [25-OH-D3] concentration and 331 
the change in vitamin D concentration after 12 months of treatment. This study has a longer follow-332 
up period than previous trials, with three year JSN having been shown in a previous study to be 333 
predictive of the incidence of osteoarthritis related knee surgery 35.  334 
Our results indicate that Vitamin D supplementation at a level of 800 IU daily is safe. Only 2 SAE’s 335 
were classified as possibly being related to treatment (one placebo with pancreatitis and one 336 
vitamin D with calculus ureteric). All other recorded SAE’s were unrelated to treatment.  Rates of 337 
occurrence of hypercalcaemia and hypercalciuria were comparable across treatment arms. 338 
 339 
Strengths and potential limitations 340 
 341 
A key strength of VIDEO was the inclusion of patients who were not biochemically vitamin D 342 
deficient. Laslett et al found that vitamin D deficiency was associated with incident or worsening of 343 
knee pain over a five year period 36, suggesting that vitamin D supplementation would be effective in 344 
16 
 
attenuating the progression of knee pain only in those who already show moderate deficiency. 345 
However, 50% of VIDEO participants had vitamin D insufficiency (<20 μg/L) at baseline.  346 
When analysis of treatment effect on JSN was broken down by baseline vitamin D status, no 347 
significant interactions with the treatment effect were found. Vitamin D supplementation had no 348 
effect on the change in joint space width even in subjects who were vitamin D deficient. 349 
We acknowledge limitations. The radiographs from the screening visits were read by the local PI at 350 
each centre to establish eligibility into the trial. A clinical orthopaedic fellow re-read all the baseline 351 
x-rays for the final analysis. This explains why a proportion of the baseline radiographs were 352 
determined to be K&L grade 1, while the inclusion criteria specified K&L ≥2. The difference between 353 
the definitions of the two grades relates to a possible vs. definite osteophyte, this boundary being 354 
particularly subjective. The distribution however was similar between the two groups and would be 355 
unlikely to bias the results of the trial. Of interest, it allowed us to assess the effect of vitamin D in 356 
very early OA.  357 
The proportion of participants lost to follow-up by the three year visit (16% placebo group, 21% 358 
treatment group) could be considered a limiting factor. This rate of loss is consistent with other OA 359 
trials 4, 17, 25, 37 and the sample size calculation allowed for 32% loss to follow up. An additional 360 
number of x-rays were unevaluable for JSW due to technical and logistic reasons. However, there 361 
was no evidence of a differential loss to follow up or unevaluable X-rays between treatment arms 362 
and detailed sensitivity analyses to assess the impact of missing data (described in supplementary 363 
file) were consistent with the primary analysis.  364 
 365 
Conclusions 366 
 367 
17 
 
Vitamin D supplementation, at a dose sufficient to elevate serum vitamin D3 levels by 10 μg/L in one 368 
year, did not slow the rate of JSN or lead to reduced pain, stiffness or functional loss over a three 369 
year period, when compared with placebo. On the basis of these findings we consider that vitamin D 370 
supplementation has no role in the management of knee OA. 371 
 372 
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Figure Legends 564 
 565 
Figure 1. Consort flow diagram for the VIDEO study  566 
 567 
Figure 2. Mean Joint Space Width in the medial compartment of the index knee with 95% CI’s by 568 
treatment group (N = 474). All available readings were included in primary analysis and multiple 569 
imputation was used to impute missing values, assuming all missing outcome values were missing at 570 
random, conditional on treatment and the covariates included in the imputation model. Both centre 571 
and baseline BMI were included in the imputation model.  572 
 573 
Figure 3. Scatterplot of baseline Vitamin D3 against three year change in Joint Space Width by 574 
treatment group with linear fit imposed (N = 463).  575 
 576 
 577 
 578 
 579 
 580 
 581 
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Table 1 Baseline Clinical and radiographic Characteristics as mean (sd) or number (%).  582 
 583 
 N vitamin D / 
 N Placebo 
Vitamin D 
 
Placebo  
Age (yrs) 237/237 64 (8) 64 (8) 
Sex: (% Female) 237/237 144 (61%) 145 (61%) 
Index knee: % Right 237/237 136 (57%) 146 (62%) 
BMI (kg/m2) 236/237 30 (5) 29 (5) 
Family history of knee or hip OA 236/235 113 (48%) 109 (46%) 
Heberdens nodes 237/237 145 (61%) 165 (70%) 
Bouchards nodes 237/237 71 (30%) 83 (35%) 
CMC joint OA 237/237 105 (44%) 101 (43%) 
% Bilateral knee OA 237/237 169 (71%) 166 (70%) 
% Taking analgesics 237/237 104 (44%) 98 (41%) 
% Taking glucosamine or 
chondroitin 
237/237 109 (46%) 104 (44%) 
% Taking cod liver oil 236/236 73 (31%) 78 (33%) 
WOMAC pain score  236/232  33 (18) 31 (19) 
WOMAC function score 236/232 36 (21) 35 (20) 
WOMAC stiffness score 236/231 47 (24) 43 (24) 
WOMAC total score 236/232 36 (19) 35 (19) 
    
Worst K&L grade+ (of 
medial/lateral) 
Index knee:                                    
234/236   
0  3 (1%) 3 (1%) 
1  62 (26%) 59 (25%) 
2  86 (37%) 92 (39%) 
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3  70 (30%) 66 (28%) 
4  13 (6%) 16 (7%) 
Worst K&L grade+ (of 
medial/lateral) 
Contra-lateral knee:          
   
0 234/236 2 (1%) 2 (1%) 
1  77 (33%) 87 (37%) 
2  65 (28%) 70 (30%) 
3  54 (23%) 43 (18%) 
4  29 (12%) 26 (11%) 
TKR Contra-lateral knee  7 (3%) 8 (3%) 
Medial JSW index knee (mm) † 218/219 3.49 (1.48) 3.58 (1.47) 
Lateral JSW index knee (mm) † 222/219 5.27 (1.95) 5.42 (1.87) 
Medial JSW Contra-lateral knee † 
(mm) 
214/213 3.40 (1.69) 3.62 (1.60) 
Lateral JSW Contra-lateral knee† 
(mm) 
216/212 5.38 (2.07) 
 
5.22 (1.90) 
Baseline Vitamin D3 (in µg/L)  20.7  (8.9) 20.7 (8.1) 
+Baseline X-rays were missing for 3 individuals in the vitamin D group. 1 placebo 584 
patients X-ray disc was corrupt therefore could not be read. Due to X-ray quality issues, 585 
including poor positioning, the numbers of readable JSW measures vary by region and by 586 
knee. 587 
 588 
 589 
 590 
 591 
 592 
 593 
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Table 2 Treatment effect estimates for primary and secondary outcomes 594 
 595 
Rate of change of Joint Space width 
(mm/year) 
Vitamin D  Placebo Difference [95% CI] 
Primary Outcome:    
Medial compartment index knee  -0.01  -0.08 0.08 [-0.14 to 0.29] 
Secondary Outcomes:    
Lateral compartment index knee  -0.11 -0.18 0.07 [-0.19 to 0.33] 
Medial compartment contra-lateral 
knee  
-0.03 0.03 -0.06 [-0.26 to 0.13] 
Lateral compartment contra-lateral 
knee  
-0.10 -0.07 -0.03 [-0.27 to 0.21] 
 Vitamin D  Placebo Difference [95% CI] 
Clinically significant progression   
(Medial index JSN>0.5mm)   
39%(N=92)  37%(N=88) 2% [-10% to 14%]1 
Rate of change per year Vitamin D  Placebo Difference [95% CI] 
WOMAC pain  -0.08 0.71 -0.79 [-2.31 to 0.74] 
WOMAC stiffness  -2.02 -0.50 -1.52 [-3.24 to 0.21] 
WOMAC function  0.42 1.07 -0.65 [-2.09 to 0.79] 
WOMAC total 0.11 0.84 -0.72 [-1.92 to 0.48] 
 Vitamin D 
 
Placebo  
 
Treatment x Time 
OR [95% CI] 
Odds of a higher K&L grade per year 
index knee 
1.32 1.23 1.07 [0.88 to 1.31] 
Odds of a higher K&L grade per year 
contra-lateral knee 
1.19 1.18 1.01 [0.80 to 1.27] 
Odds of higher grade in Get up and 1.00 1.04 0.96 [0.73 to 1.27] 
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go test per year 
N=474 (N=237 Vitamin D, N = 237 Placebo). WOMAC scores range from 0 to 100, 0 = no 596 
pain/disability, 100 = extreme pain/disability. Get up and Go test graded 1 - normal to 6 – abnormal. 597 
1Corresponds to a relative risk of 1.05 [0.77 to 1.44]. 598 
 599 
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Table 3 Vitamin D3 and Vitamin D2, at baseline and 12 months.  600 
 601 
 N vitamin D / 
 N Placebo 
Vitamin D  Placebo 
Baseline Vitamin D3: 232/231   
     <20 µg/L  117 (50%) 115 (50%) 
       20 µg/L  to 30 µg/L  79 (34%) 87 (38%) 
     >30 µg/L  36 (16%) 29 (12%) 
Baseline Vitamin D3 (in µg/L)  20.7  (8.9) 20.7 (8.1) 
    
Baseline Vitamin D2: 232/231   
     <2.2 µg/L  228 (98%) 218 (94%) 
     ≥2.2 µg/L  4 (2%) 13 (6%) 
Baseline Vitamin D2 (in µg/L)* 4/13 5.0 (2.7) 3.8 (1.7) 
    
12 month Vitamin D3:  206/206   
     <20 µg/L  14 (7%) 111 (54%) 
       20 µg/L  to 30 in µg/L  97 (47%) 67 (32%) 
     >30 µg/L  95 (46%) 28 (14%) 
12 month Vitamin D3 (in µg/L)  30.4 (7.7) 20.3 (8.1) 
    
12 month Vitamin D2: 206/206   
     <2.2 µg/L  203 (99%) 193 (94%) 
     ≥2.2 µg/L  3 (1%) 13 (6%) 
12 month Vitamin D2 (in µg/L)* 3/11 3.3 (0.76) 4.2 (2.3) 
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12 month change Vitamin D3 (µg/L) 201/201 9.4 (8.3) -0.8 (5.7) 
*Vitamin D2 reported in µg/L for patients with Vitamin D2 ≥2.2 µg/L only. Data presented as mean(sd) 602 
or number (%) for categorical variables. Vitamin D3 and Vitamin D2 were not available at baseline for 603 
5 vitamin D and 6 placebo patients and at 12 months for 31 vitamin D and 31 placebo patients,  for  604 
reasons unknown. 605 
 606 
 607 
 608 
 609 
 610 
 611 
 612 
 613 
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 614 
Figure 1. Consort flow diagram for the VIDEO study  615 
 616 
 617 
 618 
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 619 
Figure 2. Mean Joint Space Width in the medial compartment of the index knee with 95% CI’s by 620 
treatment group (N = 474 All available readings were included in primary analysis and multiple 621 
imputation was used to impute missing values, assuming all missing outcome values were missing at 622 
random, conditional on treatment and the covariates included in the imputation model. Both centre 623 
and baseline BMI were included in the imputation model.  624 
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 626 
Figure 3. Scatterplot of baseline Vitamin D3 against estimated three year change in Joint Space Width 627 
by treatment group with linear fit imposed (N = 463).  628 
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